Gland Pharma (NSE:GLAND) Accounts Receivable : ₹15,587 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Gland Pharma's accounts receivables for the quarter that ended in Mar. 2024 was ₹15,587 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Gland Pharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 92.51.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Gland Pharma's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was ₹130.57.

Gland Pharma Accounts Receivable Historical Data

The historical data trend for Gland Pharma's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma Accounts Receivable Chart

Gland Pharma Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Accounts Receivable

Get a 7-Day Free Trial

6,017.85

6,709.71

10,748.05

8,713.94

15,586.90

Gland Pharma Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial															8,713.94	-	13,731.37	-	15,586.90

Gland Pharma Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Gland Pharma Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Gland Pharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	15586.9	/	15374.5	*	91
=	92.51

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Gland Pharma's accounts receivable are only considered to be worth 75% of book value:

Gland Pharma's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(20913.66	+	0.75 * 15586.9	+	0.5 * 16552.37	-	19374.03
-	0	-	0)	/	164.711
=	130.57

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Gland Pharma Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Gland Pharma's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Gland Pharma (NSE:GLAND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

543245:India

Address

Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307

Website

https://www.glandpharma.com

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines